Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2-positive breast cancer?
| Autor: | Cristina Reboredo, Lucía García-Caballero, Ángel Vázquez-Boquete, Ángel Concha, Mari Paz Santiago, Aurea Molina, Tomás García-Caballero, Silvia Antolín, Eva Pérez, Lourdes Calvo, Rosalía Gallego, Joaquín Mosquera |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
0301 basic medicine Oncology medicine.medical_specialty Receptor ErbB-2 medicine.medical_treatment Breast Neoplasms Biomarkers Pharmacological Pathology and Forensic Medicine Correlation 03 medical and health sciences 0302 clinical medicine Breast cancer Trastuzumab Neoadjuvant treatment Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans HER2 Amplification skin and connective tissue diseases neoplasms Molecular Biology In Situ Hybridization Fluorescence Neoadjuvant therapy Aged Chemotherapy business.industry Gene Amplification Cell Biology General Medicine Middle Aged medicine.disease Neoadjuvant Therapy Treatment Outcome 030104 developmental biology 030220 oncology & carcinogenesis Female Breast carcinoma business medicine.drug |
| Zdroj: | Virchows Archiv. 479:853-857 |
| ISSN: | 1432-2307 0945-6317 |
| DOI: | 10.1007/s00428-021-03104-7 |
| Popis: | There are contradictory data regarding the correlation between HER2 amplification level determined by in situ hybridization and evolution after treatment with anti-HER2 therapies. The aim of this study was to correlate quantitative results of FISH (ratio HER2/CEP17 and number of HER2 signals/nucleus) with pathological response achieved after neoadjuvant treatment with trastuzumab and chemotherapy. For this purpose, we analysed 100 consecutive HER2-positive cases of breast carcinoma treated with neoadjuvant therapy. HER2 amplification determined by FISH was found in 92 of the 100 cases studied. pCR was obtained in 58% of the patients whose tumours presented amplification. In contrast, no pCR was obtained in the 8 patients with non-amplified tumours. A significant direct correlation between HER2 high amplification (HER2/CEP17 ratio > 5 or HER2 signals/nucleus > 10) and pCR was found. In conclusion, HER2 amplification levels are clinically relevant because they provide oncologists with valuable information on the possibilities of achieving pCR after neoadjuvant treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink